Multiple sclerosis update

American Journal of Managed Care

Volumn 19, Issue 16 SUPPL., 2013, Pages

  Markowitz, Clyde E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GADOLINIUM; GLUCOCORTICOID; IMMUNOGLOBULIN G ANTIBODY; MYELIN; VITAMIN D; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

BODY TEMPERATURE; BRAIN DAMAGE; DEMYELINATING DISEASE; DISEASE COURSE; DISEASES; EXPANDED DISABILITY STATUS SCALE; FATIGUE; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEREDITY; HUMAN; LIMB WEAKNESS; MEDICAL SOCIETY; MULTIPLE SCLEROSIS; MYELIN SHEATH; NEUROLOGIC DISEASE; NORTH AMERICA; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; UNITED STATES; WORLD HEALTH ORGANIZATION; ADULT; AGE DISTRIBUTION; BLOOD ANALYSIS; FEMALE; FORECASTING; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; ONSET AGE; PERSONALIZED MEDICINE; PHYSIOLOGIC MONITORING; PLASMAPHERESIS; PROCEDURES; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SEX RATIO; TRENDS;

ADULT; AGE DISTRIBUTION; AGE OF ONSET; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD CHEMICAL ANALYSIS; DISEASE PROGRESSION; FEMALE; FORECASTING; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INDIVIDUALIZED MEDICINE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PLASMAPHERESIS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; UNITED STATES;

EID: 84904981562     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(pt 3):606-616. (Pubitemid 43278223)
2. National Multiple Sclerosis Society. Fact sheet: multiple sclerosis. http://www.nationalmssociety.org/chapters/mnm/mediacenter/ factsheetmultiplesclerosis/index.aspx. Accessed August 6, 2013.
3. Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313): 1221-1231. (Pubitemid 34304266)
4. Pittock SJ, Mayr WT, McClelland RL, et al. Quality of life is favorable for most patients with multiple sclerosis: a populationbased cohort study. Arch Neurol. 2004;61(5):679-686. (Pubitemid 38637684)
5. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66(11):1696-1702. (Pubitemid 43964625)
6. Coleman CI, Sidovar MF, Roberts MS, Kohn C. Impact of mobility impairment on indirect costs and health-related quality of life in multiple sclerosis. PLoS One. 2013;8(1):e54756.
7. O'Brien JA, Ward AJ, Patrick AR, Caro J. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res. 2003;3(1):17.
8. Prescott JD, Factor S, Pill M, Levi GW. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm. 2007;13(1):44-52. (Pubitemid 46824250)
9. Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ. 2013;16(5):639-647.
10. Owens GM, Olvey EL, Skrepnek GH, Pill MW. Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies. J Manag Care Pharm. 2013;19(1, suppl A):S41-S53.
11. Multiple Sclerosis International Federation. Atlas of MS 2013. http://www.msif.org/about-ms/publications-and-resources/atlasof-ms-2013.aspx. Accessed October 18, 2013.
12. Cook SD. Does Epstein-Barr virus cause multiple sclerosis? Rev Neurol Dis. 2004;1(3):115-123.
13. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr. 2004;80(6 suppl):1678S-1688S.
14. Hernán MA, Jick SS, Logroscino G, et al. Cigarette smoking and the progression of multiple sclerosis. Brain. 2005;128(pt 6):1461-1465. (Pubitemid 40826198)
15. Robertson NP, Fraser M, Deans J, et al. Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. Brain. 1996;119(pt 2):449-455. (Pubitemid 26149360)
16. Sadovnick AD, Armstrong H, Rice GP, et al. A populationbased study of multiple sclerosis in twins: update. Ann Neurol. 1993;33(3):281-285. (Pubitemid 23081159)
17. Hansen T, Skytthe A, Stenager E, et al. Concordance for multiple sclerosis in Danish twins: an update of a nationwide study. Mult Scler. 2005;11(5):504-510. (Pubitemid 41387692)
18. Sadovnick AD, Ebers GC, Dyment DA, Risch NJ. Evidence for genetic basis of multiple sclerosis. Lancet. 1996;347(9017):1728-1730. (Pubitemid 26187551)
19. Robertson NP, O'Riordan JI, Chataway J, et al. Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis. Lancet. 1997;349(9065):1587-1590. (Pubitemid 27229138)
20. Ebers GC, Sadovnick AD, Risch NJ; Canadian Collaborative Study Group. A genetic basis for familial aggregation in multiple sclerosis. Nature. 1995;377(6545):150-151.
21. Rudick RA, Lee JC, Nakamura K, et al. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci. 2009;282(1-2):102-111.
22. Lublin FD, Reingold SC; National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46(4): 907-911. (Pubitemid 26134623)
23. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343(13):938-952.
24. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302.
25. Montalban X, Tintoré M, Swanton J, et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology. 2010;74(5):427-434.
26. Gronseth GS, Ashman EJ. Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54(9):1720-1725. (Pubitemid 30428396)
27. National Multiple Sclerosis Society. Clinically isolated syndrome (CIS). http://www.nationalmssociety.org/about-multiplesclerosis/what-we-know-about-ms/ diagnosing-ms/cis/index.aspx. Accessed August 6, 2013.
28. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain. 1998;121(pt 3):495-503. (Pubitemid 28116346)
29. Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology. 2009;72(9):800-805.
30. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169-178. (Pubitemid 34086933)
31. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study: I: clinical course and disability. Brain. 1989;112(pt 1):133-146. (Pubitemid 19056478)
32. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33(11):1444-1452. (Pubitemid 14237132)
33. Bornstein MB, Miller A, Slagle S, et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology. 1991;41(4):533-539.
34. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial: the Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268-1276.
35. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I: clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology. 1993;43(4):655-661.
36. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45(7):1277-1285.
37. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
38. Phillips JT, Giovannoni G, Lublin FD, et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler. 2011;17(8):970-979.
39. Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain. 2003;126(pt 2):433-437. (Pubitemid 36172747)
40. Rocca MA, Mezzapesa DM, Falini A, et al. Evidence for axonal pathology and adaptive cortical reorganization in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis. Neuroimage. 2003;18(4):847-855. (Pubitemid 36513459)
41. National Multiple Sclerosis Society. Disease management consensus statement. http://www.nationalmssociety.org/aboutmultiple-sclerosis/what-we- know-about-ms/treatments/index.aspx. Published 2008. Accessed August 6, 2013.
42. Betaseron [prescribing information]. Montville, NJ: Bayer HealthCare Pharmaceuticals Inc; 2013.
43. Extavia [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
44. Avonex [prescribing information]. Cambridge, MA: Biogen Idec Inc; 2013.
45. Rebif [prescribing information]. Rockland, MA: EMD Serono, Inc; 2012.
46. Copaxone [prescribing information]. Kansas City, MO: Teva Neuroscience, Inc; 2012.
47. Novantrone [prescribing information]. Rockland, MA: EMD Serono, Inc; 2012.
48. Tysabri [prescribing information]. Cambridge, MA: Biogen. Idec, Inc; San Diego, CA: Elan Pharmaceuticals, Inc; 2013.
49. Ampyra [prescribing information]. Ardsley, NY: Acorda Therapeutics Inc; 2013.
50. Gilenya [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
51. Aubagio [prescribing information]. Cambridge, MA: Genzyme Corporation; 2012.
52. Tecfidera [prescribing information]. Cambridge, MA: Biogen Idec Inc; 2013.
53. Safety and efficacy of orally administered laquinimod versus placebo for treatment of relapsing remitting multiple sclerosis (RRMS) (ALLEGRO). ClinicalTrials.gov website. http://clinicaltrials.gov/show/NCT00509145.
54. Study of alemtuzumab in treatment refractory MS subjects/ alemtuzumab naïve & alemtuzumab experienced subjects. ClinicalTrials.gov website. http://clinicaltrials.gov/ct2/show/NCT01624714.
55. A study of ocrelizumab in comparison with interferon beta-1a (Rebif) in patients with relapsing multiple sclerosis. ClinicalTrials.gov website. http://clinicaltrials.gov/ct2/show/NCT01247324.